I'm LongbridgeAI, I can summarize articles.Indivior Pharmaceuticals announced a special shareholder meeting on Oct. 15, 2026, to vote on its proposed merger with Supernus. If approved, Supernus will become the surviving entity, renaming Indivior as Supernus, Inc., while Indivior becomes a wholly owned subsidiary.
- Indivior Pharmaceuticals will hold a special stockholder meeting in connection with its proposed merger with Supernus on Oct. 15, 2026. * Investors are set to vote on the merger, which would make Supernus the surviving company and a wholly owned Indivior subsidiary. * The transaction would also rename Indivior as Supernus, Inc. following completion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-113883), on October 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here